| Ticker Details |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$643.65M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.81%
|
| Avg Daily Range (30 D): |
$0.85 | 2.27%
|
| Avg Daily Range (90 D): |
$1.16 | 2.95%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
.26M |
| Avg Daily Volume (90 D): |
.42M |
| Trade Size |
| Avg Trade Size (Sh.): |
97 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
51 |
| Institutional Trades |
| Total Institutional Trades: |
1,812 |
| Avg Institutional Trade: |
$1.43M |
| Avg Institutional Trade (30 D): |
$1.52M |
| Avg Institutional Trade (90 D): |
$2.17M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.65M |
| Avg Closing Trade (30 D): |
$1.61M |
| Avg Closing Trade (90 D): |
$2.22M |
| Avg Closing Volume: |
56.61K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$6.33
|
$1.55
|
$3.33
|
|
Diluted EPS
|
$6.19
|
$1.46
|
$3.28
|
|
Revenue
|
$282.08M
|
$69.46M
|
$101.69M
|
|
Gross Profit
|
$262.62M
|
$64.71M
|
$97.18M
|
|
Net Income / Loss
|
$113.3M
|
$27.9M
|
$59.61M
|
|
Operating Income / Loss
|
$118.95M
|
$28.42M
|
$61.1M
|
|
Cost of Revenue
|
$19.46M
|
$4.75M
|
$4.5M
|
|
Net Cash Flow
|
$-3.1M
|
$-4.87M
|
$7.68M
|
|
PE Ratio
|
5.58
|
|
|
| Splits |
|
Jun 27, 2024
|
1:10
|
|
Jun 25, 2003
|
1:9
|
|
|
|
